Infusion 51a's Press Releases
Our Portfolio Companies' Press Releases
Infusion 51a Executives Participate in the 5th Annual Combined Gulf Cancer Conference in Sharjah, UAE
Sharjah, UAE, November 23rd, 2022 – Infusion 51a, an impact investment fund based in the US in its fourth trip to the Middle East this
Infusion 51a Executives attend two major events: the Formula 1 Race in Abu Dhabi and the DP World Tour Championship in Dubai
Abu Dhabi and Dubai, UAE. November 20th, 2022. Infusion 51a, an impact investment fund based in the US in its fourth trip to the Middle
Infusion 51a Executives attend the Abu Dhabi Finance Week 2022, a Highlight during their Middle East trip
From left to right: Infusion 51a’s General Partner, Mr. Scott VanderMeer, and Director of Strategic Growth in the MENA Region, Mr. Mehrab Ajalli Abu Dhabi,
Infusion 51a steps into Dubai attending the Healthcare Future Summit
Left to right: Ms. Sion Hau, Ms. Maryam Siddique, Dr. Louiza Chitour, Ms. Kawthar Bukhari, Mr. Scott VanderMeer and Mr. Mehrab Ajalli Dubai, UAE and
Infusion 51a attends its first event in Bahrain: the MENA Angel Investors Summit
From left to right: Mr. Nawaf Mohamed Alkoheji, Scott VanderMeer, Mehrab Ajalli and Mr. Mishari Yousef. Manama, Bahrain, November 14th, 2022 – Infusion 51a, an
Infusion 51a launched disruptive cancer awareness campaign with over 50 local students across the streets of Dubai
Based on the premise that “there is a person behind each diagnosis,” #FACESNOTNUMBERS is a campaign that seeks to humanize statistics by portraying the experiences
Our Portfolio Companies' Press Releases
Our Portfolio Companies' Press Releases
Theralink® Technologies Receives Final Medicare Reimbursement Rate Determination and PTAN Enrollment
Important Milestone Toward Enabling Increased Access and Insight for Patients With Advanced Breast Cancer Through Theralink’s Precision Oncology Test Golden, Colorado — November 14, 2022
Theralink® Technologies Appoints Dr. Mattia Cremona as its Director of its Biopharma Laboratory
Seasoned Cancer Research Fellow with specialized interest in Reverse Phase Protein Array Technology to bolster Theralink’s management team Golden, Colorado—November 7, 2022 — Theralink Technologies, Inc.
Vivacitas Oncology Presents for the Second Year in a row at the 2022 SAPA Conference
Somerset, NJ, USA, October 1, 2022 – Vivacitas Oncology, Inc. (“Vivacitas” or the “Company”), a privately-held oncology company focused on tough–to–treat cancers, presents on October
Vivacitas Oncology Appoints Harvard Professor of Medicine Dr. David Reardon, MD to the Company’s Neuro-Oncology Medical Advisory Board
Walnut Creek, CA, USA, March 21, 2022 – Vivacitas Oncology, Inc. (“Vivacitas” or the “Company”), a privately-held oncology company focused on tough–to–treat cancers, is honored
Dr. Gerard Blobe, MD, PhD Joins Vivacitas Oncology’s Solid Tumor Medical Advisory Board
Walnut Creek, CA, USA, March 7th, 2022 – Vivacitas Oncology, Inc., a privately-held oncology company focused on tough–to–treat cancers, proudly announces that Dr. Gerard Blobe,
Vivacitas Oncology to Present at the 2022 BIO CEO & Investor Conference
Walnut Creek, CA, USA, February 14th, 2022 – Vivacitas Oncology, Inc., a privately-held biopharmaceutical company focused on tough–to–treat cancers, will present at the upcoming 2022